Loading...

W. Martin Kast, PhD

Title(s)Professor of Molecular Microbiology & Immunology, Obstetrics & Gynecology and Urology
Phone+1 323 442 3870
vCardDownload vCard
    Other Positions
    Title(s)Walter A. Richter Cancer Research Chair

    Title(s)Director Medical Biology Graduate Program


    Collapse Biography 
    Collapse Education and Training
    University of Amsterdam, AmsterdamPhD07/1987Medicine
    University of Amsterdam, AmsterdamMS05/1983Medical Biology
    University of Amsterdam, AmsterdamBS11/1980Biology
    Collapse Awards and Honors
    Affymetrix2016Affymetrix Prize
    Rare Genomics Institute2015BeHeard Ultimate Prize
    STOP Cancer2015STOP Cancer Award
    University of Southern California2014Mellon Award for Graduate Student Mentoring
    University of Amsterdam2012Landsteiner Prize
    World Scientist Forum2010North American Immunologist of the Year
    IRPC2010Eminent Scientist of the Year
    Royal Netherlands Academy of Arts and Sciences1991  - 1995Royal Netherlands Academy of Arts & Sciences Award
    Netherlands Cancer Institute1991Antoni van Leeuwenhoek Prize

    Collapse Overview 
    Collapse Overview
    W. Martin Kast, PhD is a Professor of Molecular Microbiology & Immunology, Obstetrics & Gynecology and Urology at the Norris Comprehensive Cancer Center (NCCC) of the University of Southern California in Los Angeles, CA. He holds the Walter A. Richter Cancer Research Chair and is the co-director of the NCCC Tumor Micro-environment program, the Director of the USC Medical Biology Graduate Program, a member of the USC Graduate School Admissions Committee, the Director of the Beckman Center for Immune Monitoring and the Assistant Dean of Academic Integrity. A native of the Netherlands, he earned his BS, MS, and PhD summa cum laude, from the University of Amsterdam in the Netherlands. He has and is serving on multiple Study Sections including the National Institute of Health and the Cancer Prevention and Research Institute of Texas. His research involves the design of therapeutic cancer vaccines directed against human papilloma virus (HPV) and prostate cancer. Several of his therapeutic HPV vaccines have or are currently been tried out in clinical trials. He studies how HPV enters cells and also studies the interaction of HPV with the human immune system to find out how HPV escapes immune detection and how to reverse that. He has published over 270 articles that have been quoted more than 21,000 times and lead to a publication h-index of 77. He is also the inventor on 18 patents. His research is supported by NIH and DOD grants. He is a recipient of the 1991 Antoni van Leeuwenhoek award, the 1991 Royal Netherlands Academy of Arts and Sciences award, the 2010 IRPC Eminent Scientist of the year Award for the USA, the 2012 Landsteiner Prize, the 2014 Mellon Award for graduate student mentoring, the 2015 STOP Cancer Award, the 2015 BeHEARD Award and the 2016 Affymetrix prize. He is an associate editor for the Journal of Translational Medicine, International Reviews of Immunology, HPV Today and Papillomavirus research. He also serves as the secretary/treasurer of the International Papillomavirus Society and on the advisory board of 4 biotechnology companies. In his free time he is a Scoutmaster and an actor.

    Collapse Research 
    Collapse Research Activities and Funding
    Exploration of novel pan-HPV treatments to block development of AIDS-associated c
    NIH/NCI RC2CA148298Sep 29, 2009 - Aug 31, 2011
    Role: Principal Investigator
    IMMUNE SUPPRESSION AND IMMUNE ESCAPE IN TUMOR MODELS
    NIH/NCI R01CA078399Aug 5, 1998 - May 31, 2003
    Role: Principal Investigator
    HPV AND ANTIGEN PRESENTING CELLS
    NIH/NCI R01CA074397Jun 1, 1997 - Jul 31, 2021
    Role: Principal Investigator
    CELLULAR IMMUNITY AGAINST HPV-INDUCED TUMORS
    NIH/NCI R01CA057933May 15, 1993 - Apr 30, 1995
    Role: Principal Investigator

    Collapse ORNG Applications 
    Collapse Websites
    Collapse In The News
    Collapse Faculty Mentoring
    Collapse Featured Videos

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Da Silva DM, Skeate JG, Chavez-Juan E, Lühen KP, Wu JM, Wu CM, Kast WM, Hwang K. Therapeutic efficacy of a human papillomavirus type 16 E7 bacterial exotoxin fusion protein adjuvanted with CpG or GPI-0100 in a preclinical mouse model for HPV-associated disease. Vaccine. 2019 May 16; 37(22):2915-2924. PMID: 31010714.
      View in: PubMed
    2. Taylor JR, Skeate JG, Kast WM. Annexin A2 in Virus Infection. Front Microbiol. 2018; 9:2954. PMID: 30568638.
      View in: PubMed
    3. Brunette LL, Mhawech-Fauceglia PY, Ji L, Skeate JG, Brand HE, Lawrenson K, Walia S, Chiriva-Internati M, Groshen S, Roman LD, Kast WM, Da Silva DM. Validity and prognostic significance of sperm protein 17 as a tumor biomarker for epithelial ovarian cancer: a retrospective study. BMC Cancer. 2018 Oct 11; 18(1):970. PMID: 30309325.
      View in: PubMed
    4. Rodrigues LLS, Morgado MG, Sahasrabuddhe VV, De Paula VS, Oliveira NS, Chavez-Juan E, Da Silva DM, Kast WM, Nicol AF, Pilotto JH. Cervico-vaginal self-collection in HIV-infected and uninfected women from Tapajós region, Amazon, Brazil: High acceptability, hrHPV diversity and risk factors. Gynecol Oncol. 2018 10; 151(1):102-110. PMID: 30087059.
      View in: PubMed
    5. Taylor JR, Fernandez DJ, Thornton SM, Skeate JG, Lühen KP, Da Silva DM, Langen R, Kast WM. Heterotetrameric annexin A2/S100A10 (A2t) is essential for oncogenic human papillomavirus trafficking and capsid disassembly, and protects virions from lysosomal degradation. Sci Rep. 2018 Aug 03; 8(1):11642. PMID: 30076379.
      View in: PubMed
    6. Woodham AW, Cheloha RW, Ling J, Rashidian M, Kolifrath SC, Mesyngier M, Duarte JN, Bader JM, Skeate JG, Da Silva DM, Kast WM, Ploegh HL. Nanobody-Antigen Conjugates Elicit HPV-Specific Antitumor Immune Responses. Cancer Immunol Res. 2018 07; 6(7):870-880. PMID: 29792298.
      View in: PubMed
    7. Skeate JG, Da Silva DM, Chavez-Juan E, Anand S, Nuccitelli R, Kast WM. Nano-Pulse Stimulation induces immunogenic cell death in human papillomavirus-transformed tumors and initiates an adaptive immune response. PLoS One. 2018; 13(1):e0191311. PMID: 29324830.
      View in: PubMed
    8. McCloskey JC, Kast WM, Flexman JP, McCallum D, French MA, Phillips M. Syndemic synergy of HPV and other sexually transmitted pathogens in the development of high-grade anal squamous intraepithelial lesions. Papillomavirus Res. 2017 12; 4:90-98. PMID: 29179876.
      View in: PubMed
    9. Mirandola L, Pedretti E, Figueroa JA, Chiaramonte R, Colombo M, Chapman C, Grizzi F, Patrinicola F, Kast WM, Nguyen DD, Rahman RL, Daver N, Ruvolo P, Post SM, Bresalier RS, Chiriva-Internati M. Cancer testis antigen Sperm Protein 17 as a new target for triple negative breast cancer immunotherapy. Oncotarget. 2017 Sep 26; 8(43):74378-74390. PMID: 29088794.
      View in: PubMed
    10. García-Hernández ML, Uribe-Uribe NO, Espinosa-González R, Kast WM, Khader SA, Rangel-Moreno J. A Unique Cellular and Molecular Microenvironment Is Present in Tertiary Lymphoid Organs of Patients with Spontaneous Prostate Cancer Regression. Front Immunol. 2017; 8:563. PMID: 28567040.
      View in: PubMed
    11. Woodham AW, Yan L, Skeate JG, van der Veen D, Brand HH, Wong MK, Da Silva DM, Kast WM. T cell ignorance is bliss: T cells are not tolerized by Langerhans cells presenting human papillomavirus antigens in the absence of costimulation. Papillomavirus Res. 2016 12; 2:21-30. PMID: 27182559.
      View in: PubMed
    12. Woodham AW, Sanna AM, Taylor JR, Skeate JG, Da Silva DM, Dekker LV, Kast WM. Annexin A2 antibodies but not inhibitors of the annexin A2 heterotetramer impair productive HIV-1 infection of macrophages in vitro. Virol J. 2016 11 18; 13(1):187. PMID: 27863502.
      View in: PubMed
    13. Wüstenhagen E, Hampe L, Boukhallouk F, Schneider MA, Spoden GA, Negwer I, Koynov K, Kast WM, Florin L. The Cytoskeletal Adaptor Obscurin-Like 1 Interacts with the Human Papillomavirus 16 (HPV16) Capsid Protein L2 and Is Required for HPV16 Endocytosis. J Virol. 2016 Dec 01; 90(23):10629-10641. PMID: 27654294.
      View in: PubMed
    14. Pulido MA, DerHartunian MK, Qin Z, Chung EM, Kang DS, Woodham AW, Tsou JA, Klooster R, Akbari O, Wang L, Kast WM, Liu SV, Verschuuren JJGM, Aswad DW, Laird-Offringa IA. Isoaspartylation appears to trigger small cell lung cancer-associated autoimmunity against neuronal protein ELAVL4. J Neuroimmunol. 2016 10 15; 299:70-78. PMID: 27725125.
      View in: PubMed
    15. Nicol AF, Brunette LL, Nuovo GJ, Grinsztejn B, Friedman RK, Veloso VG, Cunha CB, Coutinho JR, Vianna-Andrade C, Oliveira NS, Woodham AW, DA Silva DM, Kast WM. Secretory Leukocyte Protease Inhibitor Expression and High-Risk HPV Infection in Anal Lesions of HIV-Positive Patients. J Acquir Immune Defic Syndr. 2016 09 01; 73(1):27-33. PMID: 27149102.
      View in: PubMed
    16. Woodham AW, Skeate JG, Sanna AM, Taylor JR, Da Silva DM, Cannon PM, Kast WM. Human Immunodeficiency Virus Immune Cell Receptors, Coreceptors, and Cofactors: Implications for Prevention and Treatment. AIDS Patient Care STDS. 2016 07; 30(7):291-306. PMID: 27410493.
      View in: PubMed
    17. Skeate JG, Woodham AW, Einstein MH, Da Silva DM, Kast WM. Current therapeutic vaccination and immunotherapy strategies for HPV-related diseases. Hum Vaccin Immunother. 2016 06 02; 12(6):1418-29. PMID: 26835746.
      View in: PubMed
    18. Da Silva DM, Woodham AW, Naylor PH, Egan JE, Berinstein NL, Kast WM. Immunostimulatory Activity of the Cytokine-Based Biologic, IRX-2, on Human Papillomavirus-Exposed Langerhans Cells. J Interferon Cytokine Res. 2016 05; 36(5):291-301. PMID: 26653678.
      View in: PubMed
    19. Da Silva DM, Woodham AW, Rijkee LK, Skeate JG, Taylor JR, Koopman ME, Brand HE, Wong MK, McKee GM, Salazar AM, Kast WM. Human papillomavirus-exposed Langerhans cells are activated by stabilized Poly-I:C. Papillomavirus Res. 2015 Dec 01; 1:12-21. PMID: 26665182.
      View in: PubMed
    20. Skeate JG, Porras TB, Woodham AW, Jang JK, Taylor JR, Brand HE, Kelly TJ, Jung JU, Da Silva DM, Yuan W, Kast WM. Herpes simplex virus downregulation of secretory leukocyte protease inhibitor enhances human papillomavirus type 16 infection. J Gen Virol. 2016 Feb; 97(2):422-34. PMID: 26555393.
      View in: PubMed
    21. Da Silva DM, Woodham AW, Skeate JG, Rijkee LK, Taylor JR, Brand HE, Muderspach LI, Roman LD, Yessaian AA, Pham HQ, Matsuo K, Lin YG, McKee GM, Salazar AM, Kast WM. Langerhans cells from women with cervical precancerous lesions become functionally responsive against human papillomavirus after activation with stabilized Poly-I:C. Clin Immunol. 2015 Dec; 161(2):197-208. PMID: 26360252.
      View in: PubMed
    22. Bogaert L, Woodham AW, Da Silva DM, Martens A, Meyer E, Kast WM. A novel murine model for evaluating bovine papillomavirus prophylactics/therapeutics for equine sarcoid-like tumours. J Gen Virol. 2015 Sep; 96(9):2764-8. PMID: 26044793.
      View in: PubMed
    23. Woodham AW, Taylor JR, Jimenez AI, Skeate JG, Schmidt T, Brand HE, Da Silva DM, Kast WM. Small molecule inhibitors of the annexin A2 heterotetramer prevent human papillomavirus type 16 infection. J Antimicrob Chemother. 2015; 70(6):1686-90. PMID: 25712315.
      View in: PubMed
    24. Yan L, Woodham AW, Da Silva DM, Kast WM. Functional analysis of HPV-like particle-activated Langerhans cells in vitro. Methods Mol Biol. 2015; 1249:333-50. PMID: 25348318.
      View in: PubMed
    25. Woodham AW, Raff AB, Da Silva DM, Kast WM. Molecular analysis of human papillomavirus virus-like particle activated Langerhans cells in vitro. Methods Mol Biol. 2015; 1249:135-49. PMID: 25348303.
      View in: PubMed
    26. Yan L, Da Silva DM, Verma B, Gray A, Brand HE, Skeate JG, Porras TB, Kanodia S, Kast WM. Forced LIGHT expression in prostate tumors overcomes Treg mediated immunosuppression and synergizes with a prostate tumor therapeutic vaccine by recruiting effector T lymphocytes. Prostate. 2015 Feb 15; 75(3):280-91. PMID: 25399517.
      View in: PubMed
    27. Woodham AW, Raff AB, Raff LM, Da Silva DM, Yan L, Skeate JG, Wong MK, Lin YG, Kast WM. Inhibition of Langerhans cell maturation by human papillomavirus type 16: a novel role for the annexin A2 heterotetramer in immune suppression. J Immunol. 2014 May 15; 192(10):4748-57. PMID: 24719459.
      View in: PubMed
    28. Da Silva DM, Movius CA, Raff AB, Brand HE, Skeate JG, Wong MK, Kast WM. Suppression of Langerhans cell activation is conserved amongst human papillomavirus a and ß genotypes, but not a µ genotype. Virology. 2014 Mar; 452-453:279-86. PMID: 24606705.
      View in: PubMed
    29. Raff AB, Woodham AW, Raff LM, Skeate JG, Yan L, Da Silva DM, Schelhaas M, Kast WM. The evolving field of human papillomavirus receptor research: a review of binding and entry. J Virol. 2013 Jun; 87(11):6062-72. PMID: 23536685.
      View in: PubMed
    30. Hoffmann M, Quabius ES, Tribius S, Hebebrand L, Görögh T, Halec G, Kahn T, Hedderich J, Röcken C, Haag J, Waterboer T, Schmitt M, Giuliano AR, Kast WM. Human papillomavirus infection in head and neck cancer: the role of the secretory leukocyte protease inhibitor. Oncol Rep. 2013 May; 29(5):1962-8. PMID: 23467841.
      View in: PubMed
    31. Bot A, Ahn M, Bosch M, Brockstedt D, Butterfield LH, Cornforth A, Harrop R, Kast WM, Koya R, Marincola F, Margolin K, McCoy C, Pawelec G, Rothman J, Ramirez-Montagut T, Schlom J, Srivastava P, Wallis S, Walter S, Wang E, Waslif J. A novel series of conferences tackling the hurdles confronting the translation of novel cancer immunotherapies. J Transl Med. 2012 Nov 05; 10:218. PMID: 23127127.
      View in: PubMed
    32. Pandey A, Kurup A, Shrivastava A, Radhi S, Nguyen DD, Arentz C, D'Chuna N, Hardwick F, D'Souza MJ, Jenkins M, Grizzi F, Kast WM, Cobos E, Rahman R, Chiriva-Internati M, Chiaramonte R, Platonova N. Cancer testes antigens in breast cancer: biological role, regulation, and therapeutic applicability. Int Rev Immunol. 2012 Oct; 31(5):302-20. PMID: 23083343.
      View in: PubMed
    33. Woodham AW, Da Silva DM, Skeate JG, Raff AB, Ambroso MR, Brand HE, Isas JM, Langen R, Kast WM. The S100A10 subunit of the annexin A2 heterotetramer facilitates L2-mediated human papillomavirus infection. PLoS One. 2012; 7(8):e43519. PMID: 22927980.
      View in: PubMed
    34. Jenkins M, Chiriva-Internati M, Mirandola L, Tonroy C, Tedjarati SS, Davis N, D'Cunha N, Tijani L, Hardwick F, Nguyen D, Kast WM, Cobos E. Perspective for prophylaxis and treatment of cervical cancer: an immunological approach. Int Rev Immunol. 2012 Feb; 31(1):3-21. PMID: 22251005.
      View in: PubMed
    35. Chiriva-Internati M, Kast WM, Bot A. In this issue: targeting Human Papilloma Virus-associated disease, from cervical to head and neck carcinoma…and more. Int Rev Immunol. 2012 Feb; 31(1):1-2. PMID: 22251004.
      View in: PubMed
    36. Schutt C, Bumm K, Mirandola L, Bernardini G, Cunha N, Tijani L, Nguyen D, Cordero J, Jenkins MR, Cobos E, Kast WM, Chiriva-Internati M. Immunological treatment options for locoregionally advanced head and neck squamous cell carcinoma. Int Rev Immunol. 2012 Feb; 31(1):22-42. PMID: 22251006.
      View in: PubMed
    37. Mirandola L, Chiriva-Internati M, Montagna D, Locatelli F, Zecca M, Ranzani M, Basile A, Locati M, Cobos E, Kast WM, Asselta R, Paraboschi EM, Comi P, Chiaramonte R. Notch1 regulates chemotaxis and proliferation by controlling the CC-chemokine receptors 5 and 9 in T cell acute lymphoblastic leukaemia. J Pathol. 2012 Apr; 226(5):713-22. PMID: 21984373.
      View in: PubMed
    38. Mirandola L, Comi P, Cobos E, Kast WM, Chiriva-Internati M, Chiaramonte R. Notch-ing from T-cell to B-cell lymphoid malignancies. Cancer Lett. 2011 Sep 01; 308(1):1-13. PMID: 21652011.
      View in: PubMed
    39. Chiriva-Internati M, Mirandola L, Yu Y, Jenkins MR, Gornati R, Bernardini G, Gioia M, Chiaramonte R, Cannon MJ, Kast WM, Cobos E. Cancer testis antigen, ropporin, is a potential target for multiple myeloma immunotherapy. J Immunother. 2011 Jul-Aug; 34(6):490-9. PMID: 21654522.
      View in: PubMed
    40. Chiriva-Internati M, Yu Y, Mirandola L, D'Cunha N, Hardwicke F, Cannon MJ, Cobos E, Kast WM. Identification of AKAP-4 as a new cancer/testis antigen for detection and immunotherapy of prostate cancer. Prostate. 2012 Jan; 72(1):12-23. PMID: 21520158.
      View in: PubMed
    41. Cordes C, Häsler R, Werner C, Görögh T, Röcken C, Hebebrand L, Kast WM, Hoffmann M, Schreiber S, Ambrosch P. The level of secretory leukocyte protease inhibitor is decreased in metastatic head and neck squamous cell carcinoma. Int J Oncol. 2011 Jul; 39(1):185-91. PMID: 21503571.
      View in: PubMed
    42. Mirandola L, J Cannon M, Cobos E, Bernardini G, Jenkins MR, Kast WM, Chiriva-Internati M. Cancer testis antigens: novel biomarkers and targetable proteins for ovarian cancer. Int Rev Immunol. 2011 Apr-Jun; 30(2-3):127-37. PMID: 21557639.
      View in: PubMed
    43. Chiriva-Internati M, Mirandola L, Kast WM, Jenkins MR, Cobos E, Cannon MJ. Understanding the cross-talk between ovarian tumors and immune cells: mechanisms for effective immunotherapies. Int Rev Immunol. 2011 Apr-Jun; 30(2-3):71-86. PMID: 21557635.
      View in: PubMed
    44. Gray A, Yan L, Kast WM. Prevention is better than cure: the case for clinical trials of therapeutic cancer vaccines in the prophylactic setting. Mol Interv. 2010 Aug; 10(4):197-203. PMID: 20729485.
      View in: PubMed
    45. Bogaert L, Martens A, Kast WM, Van Marck E, De Cock H. Bovine papillomavirus DNA can be detected in keratinocytes of equine sarcoid tumors. Vet Microbiol. 2010 Dec 15; 146(3-4):269-75. PMID: 21095508.
      View in: PubMed
    46. Chiriva-Internati M, Yu Y, Mirandola L, Jenkins MR, Chapman C, Cannon M, Cobos E, Kast WM. Cancer testis antigen vaccination affords long-term protection in a murine model of ovarian cancer. PLoS One. 2010 May 12; 5(5):e10471. PMID: 20485677.
      View in: PubMed
    47. Kanodia S, Da Silva DM, Karamanukyan T, Bogaert L, Fu YX, Kast WM. Expression of LIGHT/TNFSF14 combined with vaccination against human papillomavirus Type 16 E7 induces significant tumor regression. Cancer Res. 2010 May 15; 70(10):3955-64. PMID: 20460520.
      View in: PubMed
    48. Clark JI, Moon J, Hutchins LF, Sosman JA, Kast WM, Da Silva DM, Liu PY, Thompson JA, Flaherty LE, Sondak VK. Phase 2 trial of combination thalidomide plus temozolomide in patients with metastatic malignant melanoma: Southwest Oncology Group S0508. Cancer. 2010 Jan 15; 116(2):424-31. PMID: 19918923.
      View in: PubMed
    49. Gray A, de la Luz Garcia-Hernandez M, van West M, Kanodia S, Hubby B, Kast WM. Prostate cancer immunotherapy yields superior long-term survival in TRAMP mice when administered at an early stage of carcinogenesis prior to the establishment of tumor-associated immunosuppression at later stages. Vaccine. 2009 Dec 30; 27 Suppl 6:G52-9. PMID: 20006141.
      View in: PubMed
    50. Adelstein DJ, Ridge JA, Gillison ML, Chaturvedi AK, D'Souza G, Gravitt PE, Westra W, Psyrri A, Kast WM, Koutsky LA, Giuliano A, Krosnick S, Trotti A, Schuller DE, Forastiere A, Ullmann CD. Head and neck squamous cell cancer and the human papillomavirus: summary of a National Cancer Institute State of the Science Meeting, November 9-10, 2008, Washington, D.C. Head Neck. 2009 Nov; 31(11):1393-422. PMID: 19787782.
      View in: PubMed
    51. Fahey LM, Raff AB, Da Silva DM, Kast WM. A major role for the minor capsid protein of human papillomavirus type 16 in immune escape. J Immunol. 2009 Nov 15; 183(10):6151-6. PMID: 19864613.
      View in: PubMed
    52. Smith KA, Meisenburg BL, Tam VL, Pagarigan RR, Wong R, Joea DK, Lantzy L, Carrillo MA, Gross TM, Malyankar UM, Chiang CS, Da Silva DM, Kündig TM, Kast WM, Qiu Z, Bot A. Lymph node-targeted immunotherapy mediates potent immunity resulting in regression of isolated or metastatic human papillomavirus-transformed tumors. Clin Cancer Res. 2009 Oct 01; 15(19):6167-76. PMID: 19789304.
      View in: PubMed
    53. Chiriva-Internati M, Gagliano N, Donetti E, Costa F, Grizzi F, Franceschini B, Albani E, Levi-Setti PE, Gioia M, Jenkins M, Cobos E, Kast WM. Sperm protein 17 is expressed in the sperm fibrous sheath. J Transl Med. 2009 Jul 15; 7:61. PMID: 19604394.
      View in: PubMed
    54. Hitzeroth II, Passmore JA, Shephard E, Stewart D, Müller M, Williamson AL, Rybicki EP, Kast WM. Immunogenicity of an HPV-16 L2 DNA vaccine. Vaccine. 2009 Oct 30; 27(46):6432-4. PMID: 19559114.
      View in: PubMed
    55. Koh YT, Gray A, Higgins SA, Hubby B, Kast WM. Androgen ablation augments prostate cancer vaccine immunogenicity only when applied after immunization. Prostate. 2009 May 01; 69(6):571-84. PMID: 19143030.
      View in: PubMed
    56. Fahey LM, Raff AB, Da Silva DM, Kast WM. Reversal of human papillomavirus-specific T cell immune suppression through TLR agonist treatment of Langerhans cells exposed to human papillomavirus type 16. J Immunol. 2009 Mar 01; 182(5):2919-28. PMID: 19234187.
      View in: PubMed
    57. Leffers N, Gooden MJ, Mokhova AA, Kast WM, Boezen HM, Ten Hoor KA, Hollema H, Daemen T, van der Zee AG, Nijman HW. Down-regulation of proteasomal subunit MB1 is an independent predictor of improved survival in ovarian cancer. Gynecol Oncol. 2009 May; 113(2):256-63. PMID: 19243813.
      View in: PubMed
    58. Yu Y, Pilgrim P, Zhou W, Gagliano N, Frezza EE, Jenkins M, Weidanz JA, Lustgarten J, Cannon M, Bumm K, Cobos E, Kast WM, Chiriva-Internati M. rAAV/Her-2/neu loading of dendritic cells for a potent cellular-mediated MHC class I restricted immune response against ovarian cancer. Viral Immunol. 2008 Dec; 21(4):435-42. PMID: 19115932.
      View in: PubMed
    59. Kanodia S, Kast WM. Peptide-based vaccines for cancer: realizing their potential. Expert Rev Vaccines. 2008 Dec; 7(10):1533-45. PMID: 19053209.
      View in: PubMed
    60. Raff AB, Gray A, Kast WM. Prostate stem cell antigen: a prospective therapeutic and diagnostic target. Cancer Lett. 2009 May 18; 277(2):126-32. PMID: 18838214.
      View in: PubMed
    61. Yu Y, Pilgrim P, Yan J, Zhou W, Jenkins M, Gagliano N, Bumm K, Cannon M, Milzani A, Dalle-Donne I, Kast WM, Cobos E, Chiriva-Internati M. Protective CD8+ T-cell responses to cytomegalovirus driven by rAAV/GFP/IE1 loading of dendritic cells. J Transl Med. 2008 Oct 05; 6:56. PMID: 18834548.
      View in: PubMed
    62. Moore TV, Lyons GE, Brasic N, Roszkowski JJ, Voelkl S, Mackensen A, Kast WM, Le Poole IC, Nishimura MI. Relationship between CD8-dependent antigen recognition, T cell functional avidity, and tumor cell recognition. Cancer Immunol Immunother. 2009 May; 58(5):719-28. PMID: 18836717.
      View in: PubMed
    63. Chiriva-Internati M, Weidanz JA, Yu Y, Frezza EE, Jenkins MR, Kennedy RC, Cobos E, Kast WM. Sperm protein 17 is a suitable target for adoptive T-cell-based immunotherapy in human ovarian cancer. J Immunother. 2008 Oct; 31(8):693-703. PMID: 18779750.
      View in: PubMed
    64. Song LL, Peng Y, Yun J, Rizzo P, Chaturvedi V, Weijzen S, Kast WM, Stone PJ, Santos L, Loredo A, Lendahl U, Sonenshein G, Osborne B, Qin JZ, Pannuti A, Nickoloff BJ, Miele L. Notch-1 associates with IKKalpha and regulates IKK activity in cervical cancer cells. Oncogene. 2008 Oct 02; 27(44):5833-44. PMID: 18560356.
      View in: PubMed
    65. Chiriva-Internati M, Cobos E, Da Silva DM, Kast WM. Sperm fibrous sheath proteins: a potential new class of target antigens for use in human therapeutic cancer vaccines. Cancer Immun. 2008 Apr 24; 8:8. PMID: 18433090.
      View in: PubMed
    66. Gray A, Raff AB, Chiriva-Internati M, Chen SY, Kast WM. A paradigm shift in therapeutic vaccination of cancer patients: the need to apply therapeutic vaccination strategies in the preventive setting. Immunol Rev. 2008 Apr; 222:316-27. PMID: 18364011.
      View in: PubMed
    67. Garcia-Hernandez Mde L, Gray A, Hubby B, Klinger OJ, Kast WM. Prostate stem cell antigen vaccination induces a long-term protective immune response against prostate cancer in the absence of autoimmunity. Cancer Res. 2008 Feb 01; 68(3):861-9. PMID: 18245488.
      View in: PubMed
    68. Chiriva-Internati M, Ferrari R, Yu Y, Hamrick C, Gagliano N, Grizzi F, Frezza E, Jenkins MR, Hardwick F, D'Cunha N, Kast WM, Cobos E. AKAP-4: a novel cancer testis antigen for multiple myeloma. Br J Haematol. 2008 Feb; 140(4):465-8. PMID: 18217892.
      View in: PubMed
    69. Kanodia S, Da Silva DM, Kast WM. Recent advances in strategies for immunotherapy of human papillomavirus-induced lesions. Int J Cancer. 2008 Jan 15; 122(2):247-59. PMID: 17973257.
      View in: PubMed
    70. Le Poole IC, ElMasri WM, Denman CJ, Kroll TM, Bommiasamy H, Lyons Eiben G, Kast WM. Langerhans cells and dendritic cells are cytotoxic towards HPV16 E6 and E7 expressing target cells. Cancer Immunol Immunother. 2008 Jun; 57(6):789-97. PMID: 18004565.
      View in: PubMed
    71. Wong RM, Scotland RR, Lau RL, Wang C, Korman AJ, Kast WM, Weber JS. Programmed death-1 blockade enhances expansion and functional capacity of human melanoma antigen-specific CTLs. Int Immunol. 2007 Oct; 19(10):1223-34. PMID: 17898045.
      View in: PubMed
    72. Janetzki S, Panageas KS, Ben-Porat L, Boyer J, Britten CM, Clay TM, Kalos M, Maecker HT, Romero P, Yuan J, Kast WM, Hoos A. Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI). Cancer Immunol Immunother. 2008 Mar; 57(3):303-15. PMID: 17721781.
      View in: PubMed
    73. Roman LD, Wilczynski S, Muderspach LI, Burnett AF, O'Meara A, Brinkman JA, Kast WM, Facio G, Felix JC, Aldana M, Weber JS. A phase II study of Hsp-7 (SGN-00101) in women with high-grade cervical intraepithelial neoplasia. Gynecol Oncol. 2007 Sep; 106(3):558-66. PMID: 17631950.
      View in: PubMed
    74. Da Silva DM, Fausch SC, Verbeek JS, Kast WM. Uptake of human papillomavirus virus-like particles by dendritic cells is mediated by Fcgamma receptors and contributes to acquisition of T cell immunity. J Immunol. 2007 Jun 15; 178(12):7587-97. PMID: 17548594.
      View in: PubMed
    75. Daftarian PM, Mansour M, Pohajdak B, Fuentes-Ortega A, Korets-Smith E, Macdonald L, Weir G, Brown RG, Kast WM. Rejection of large HPV-16 expressing tumors in aged mice by a single immunization of VacciMax encapsulated CTL/T helper peptides. J Transl Med. 2007 Jun 07; 5:26. PMID: 17555571.
      View in: PubMed
    76. Chiriva-Internati M, Cobos E, Kast WM. Advances in immunotherapy of multiple myeloma: from the discovery of tumor-associated antigens to clinical trials. Int Rev Immunol. 2007 May-Aug; 26(3-4):197-222. PMID: 17558744.
      View in: PubMed
    77. Mansour M, Pohajdak B, Kast WM, Fuentes-Ortega A, Korets-Smith E, Weir GM, Brown RG, Daftarian P. Therapy of established B16-F10 melanoma tumors by a single vaccination of CTL/T helper peptides in VacciMax. J Transl Med. 2007 Apr 23; 5:20. PMID: 17451606.
      View in: PubMed
    78. Lambeck AJ, Crijns AP, Leffers N, Sluiter WJ, ten Hoor KA, Braid M, van der Zee AG, Daemen T, Nijman HW, Kast WM. Serum cytokine profiling as a diagnostic and prognostic tool in ovarian cancer: a potential role for interleukin 7. Clin Cancer Res. 2007 Apr 15; 13(8):2385-91. PMID: 17438097.
      View in: PubMed
    79. Chiriva-Internati M, Grizzi F, Weidanz JA, Ferrari R, Yuefei Y, Velez B, Shearer MH, Lowe DB, Frezza EE, Cobos E, Kast WM, Kennedy RC. A NOD/SCID tumor model for human ovarian cancer that allows tracking of tumor progression through the biomarker Sp17. J Immunol Methods. 2007 Apr 10; 321(1-2):86-93. PMID: 17336323.
      View in: PubMed
    80. Kanodia S, Fahey LM, Kast WM. Mechanisms used by human papillomaviruses to escape the host immune response. Curr Cancer Drug Targets. 2007 Feb; 7(1):79-89. PMID: 17305480.
      View in: PubMed
    81. Garcia-Hernandez Mde L, Gray A, Hubby B, Kast WM. In vivo effects of vaccination with six-transmembrane epithelial antigen of the prostate: a candidate antigen for treating prostate cancer. Cancer Res. 2007 Feb 01; 67(3):1344-51. PMID: 17283172.
      View in: PubMed
    82. Brinkman JA, Xu X, Kast WM. The efficacy of a DNA vaccine containing inserted and replicated regions of the E7 gene for treatment of HPV-16 induced tumors. Vaccine. 2007 Apr 30; 25(17):3437-44. PMID: 17241713.
      View in: PubMed
    83. Brinkman JA, Hughes SH, Stone P, Caffrey AS, Muderspach LI, Roman LD, Weber JS, Kast WM. Therapeutic vaccination for HPV induced cervical cancers. Dis Markers. 2007; 23(4):337-52. PMID: 17627067.
      View in: PubMed
    84. Koh YT, Higgins SA, Weber JS, Kast WM. Immunological consequences of using three different clinical/laboratory techniques of emulsifying peptide-based vaccines in incomplete Freund's adjuvant. J Transl Med. 2006 Oct 23; 4:42. PMID: 17059610.
      View in: PubMed
    85. Daftarian P, Mansour M, Benoit AC, Pohajdak B, Hoskin DW, Brown RG, Kast WM. Eradication of established HPV 16-expressing tumors by a single administration of a vaccine composed of a liposome-encapsulated CTL-T helper fusion peptide in a water-in-oil emulsion. Vaccine. 2006 Jun 12; 24(24):5235-44. PMID: 16675074.
      View in: PubMed
    86. Chiriva-Internati M, Grizzi F, Pinkston J, Morrow KJ, D'Cunha N, Frezza EE, Muzzio PC, Kast WM, Cobos E. Gamma-radiation upregulates MHC class I/II and ICAM-I molecules in multiple myeloma cell lines and primary tumors. In Vitro Cell Dev Biol Anim. 2006 Mar-Apr; 42(3-4):89-95. PMID: 16759154.
      View in: PubMed
    87. Lyons GE, Roszkowski JJ, Man S, Yee C, Kast WM, Nishimura MI. T-cell receptor tetramer binding or the lack there of does not necessitate antigen reactivity in T-cell receptor transduced T cells. Cancer Immunol Immunother. 2006 Sep; 55(9):1142-50. PMID: 16374636.
      View in: PubMed
    88. Bumm K, Grizzi F, Franceschini B, Koch M, Iro H, Wurm J, Ceva-Grimaldi G, Dimmler A, Cobos E, Dioguardi N, Sinha UK, Kast WM, Chiriva-Internati M. Sperm protein 17 expression defines 2 subsets of primary esthesioneuroblastoma. Hum Pathol. 2005 Dec; 36(12):1289-93. PMID: 16311122.
      View in: PubMed
    89. Warrino DE, Olson WC, Scarrow MI, D'Ambrosio-Brennan LJ, Guido RS, Da Silva DM, Kast WM, Storkus WJ. Human papillomavirus L1L2-E7 virus-like particles partially mature human dendritic cells and elicit E7-specific T-helper responses from patients with cervical intraepithelial neoplasia or cervical cancer in vitro. Hum Immunol. 2005 Jul; 66(7):762-72. PMID: 16112023.
      View in: PubMed
    90. Fausch SC, Fahey LM, Da Silva DM, Kast WM. Human papillomavirus can escape immune recognition through Langerhans cell phosphoinositide 3-kinase activation. J Immunol. 2005 Jun 01; 174(11):7172-8. PMID: 15905561.
      View in: PubMed
    91. Fausch SC, Da Silva DM, Kast WM. Heterologous papillomavirus virus-like particles and human papillomavirus virus-like particle immune complexes activate human Langerhans cells. Vaccine. 2005 Feb 25; 23(14):1720-9. PMID: 15705478.
      View in: PubMed
    92. Roszkowski JJ, Lyons GE, Kast WM, Yee C, Van Besien K, Nishimura MI. Simultaneous generation of CD8+ and CD4+ melanoma-reactive T cells by retroviral-mediated transfer of a single T-cell receptor. Cancer Res. 2005 Feb 15; 65(4):1570-6. PMID: 15735047.
      View in: PubMed
    93. Brinkman JA, Caffrey AS, Muderspach LI, Roman LD, Kast WM. The impact of anti HPV vaccination on cervical cancer incidence and HPV induced cervical lesions: consequences for clinical management. Eur J Gynaecol Oncol. 2005; 26(2):129-42. PMID: 15857016.
      View in: PubMed
    94. Kast WM, Levitsky H, Marincola FM. Synopsis of the 6th Walker's Cay Colloquium on Cancer Vaccines and Immunotherapy. J Transl Med. 2004 Jun 22; 2(1):20. PMID: 15212694.
      View in: PubMed
    95. Warrino DE, Olson WC, Knapp WT, Scarrow MI, D'Ambrosio-Brennan LJ, Guido RS, Edwards RP, Kast WM, Storkus WJ. Disease-stage variance in functional CD4(+) T-cell responses against novel pan-human leukocyte antigen-D region presented human papillomavirus-16 E7 epitopes. Clin Cancer Res. 2004 May 15; 10(10):3301-8. PMID: 15161683.
      View in: PubMed
    96. Schreiber K, Cannon RE, Karrison T, Beck-Engeser G, Huo D, Tennant RW, Jensen H, Kast WM, Krausz T, Meredith SC, Chen L, Schreiber H. Strong synergy between mutant ras and HPV16 E6/E7 in the development of primary tumors. Oncogene. 2004 May 13; 23(22):3972-9. PMID: 15077191.
      View in: PubMed
    97. Grizzi F, Chiriva-Internati M, Franceschini B, Bumm K, Colombo P, Ciccarelli M, Donetti E, Gagliano N, Hermonat PL, Bright RK, Gioia M, Dioguardi N, Kast WM. Sperm protein 17 is expressed in human somatic ciliated epithelia. J Histochem Cytochem. 2004 Apr; 52(4):549-54. PMID: 15034007.
      View in: PubMed
    98. Brinkman JA, Fausch SC, Weber JS, Kast WM. Peptide-based vaccines for cancer immunotherapy. Expert Opin Biol Ther. 2004 Feb; 4(2):181-98. PMID: 14998777.
      View in: PubMed
    99. Cassetti MC, McElhiney SP, Shahabi V, Pullen JK, Le Poole IC, Eiben GL, Smith LR, Kast WM. Antitumor efficacy of Venezuelan equine encephalitis virus replicon particles encoding mutated HPV16 E6 and E7 genes. Vaccine. 2004 Jan 02; 22(3-4):520-7. PMID: 14670335.
      View in: PubMed
    100. Markiewicz MA, Kast WM. Progress in the development of immunotherapy of cancer using ex vivo-generated dendritic cells expressing multiple tumor antigen epitopes. Cancer Invest. 2004; 22(3):417-34. PMID: 15493363.
      View in: PubMed
    101. Harrison JS, Kast WM. Cure of glioma: a space not yet occupied for the lesion. Cancer Invest. 2004; 22(3):479-80. PMID: 15493370.
      View in: PubMed
    102. Chiriva-Internati M, Grizzi F, Franceschini B, Hermonat PL, Bright RK, Bumm K, Dioguardi N, Kast WM. Is sperm protein 17 a useful target for tumor immunotherapy? Blood. 2003 Sep 15; 102(6):2308-9. PMID: 12959941.
      View in: PubMed
    103. Wilcox RA, Tamada K, Flies DB, Zhu G, Chapoval AI, Blazar BR, Kast WM, Chen L. Ligation of CD137 receptor prevents and reverses established anergy of CD8+ cytolytic T lymphocytes in vivo. Blood. 2004 Jan 01; 103(1):177-84. PMID: 12969968.
      View in: PubMed
    104. Mitchell MS, Kast WM. Synopsis of the 5th annual Cancer Vaccines and Immunotherapy Colloquium at Walker's Cay. Cancer Immunol Immunother. 2003 Oct; 52(10):655-60. PMID: 12942201.
      View in: PubMed
    105. Le Poole IC, Bommiasamy H, Bocchetta M, Kast WM. Advances in prophylactic cancer vaccine research. Expert Rev Anticancer Ther. 2003 Aug; 3(4):537-45. PMID: 12934665.
      View in: PubMed
    106. Da Silva DM, Schiller JT, Kast WM. Heterologous boosting increases immunogenicity of chimeric papillomavirus virus-like particle vaccines. Vaccine. 2003 Jul 04; 21(23):3219-27. PMID: 12804851.
      View in: PubMed
    107. Fausch SC, Da Silva DM, Kast WM. Differential uptake and cross-presentation of human papillomavirus virus-like particles by dendritic cells and Langerhans cells. Cancer Res. 2003 Jul 01; 63(13):3478-82. PMID: 12839929.
      View in: PubMed
    108. Kotecha MT, Afghan RK, Vasilikopoulou E, Wilson E, Marsh P, Kast WM, Davies DH, Caparros-Wanderley W. Enhanced tumour growth after DNA vaccination against human papilloma virus E7 oncoprotein: evidence for tumour-induced immune deviation. Vaccine. 2003 Jun 02; 21(19-20):2506-15. PMID: 12744885.
      View in: PubMed
    109. Le Poole IC, Bommiasamy H, Kast WM. Recent progress in tumour vaccine development. Expert Opin Investig Drugs. 2003 Jun; 12(6):971-81. PMID: 12783601.
      View in: PubMed
    110. Velders MP, Markiewicz MA, Eiben GL, Kast WM. CD4+ T cell matters in tumor immunity. Int Rev Immunol. 2003 Mar-Apr; 22(2):113-40. PMID: 12962272.
      View in: PubMed
    111. Weijzen S, Zlobin A, Braid M, Miele L, Kast WM. HPV16 E6 and E7 oncoproteins regulate Notch-1 expression and cooperate to induce transformation. J Cell Physiol. 2003 Mar; 194(3):356-62. PMID: 12548555.
      View in: PubMed
    112. Markiewicz MA, Kast WM. Advances in immunotherapy for prostate cancer. Adv Cancer Res. 2003; 87:159-94. PMID: 12641276.
      View in: PubMed
    113. Fausch SC, Da Silva DM, Eiben GL, Le Poole IC, Kast WM. HPV protein/peptide vaccines: from animal models to clinical trials. Front Biosci. 2003 Jan 01; 8:s81-91. PMID: 12456298.
      View in: PubMed
    114. Eiben GL, da Silva DM, Fausch SC, Le Poole IC, Nishimura MI, Kast WM. Cervical cancer vaccines: recent advances in HPV research. Viral Immunol. 2003; 16(2):111-21. PMID: 12828864.
      View in: PubMed
    115. Le Poole IC, Gerberi MA, Kast WM. Emerging strategies in tumor vaccines. Curr Opin Oncol. 2002 Nov; 14(6):641-8. PMID: 12409655.
      View in: PubMed
    116. Mitchell MS, Kast WM. Synopsis of the 4th Walker's Cay Meeting on Cancer Vaccines, 7-10 March 2002. Cancer Immunol Immunother. 2002 Dec; 51(11-12):674-6. PMID: 12439614.
      View in: PubMed
    117. Weijzen S, Velders MP, Elmishad AG, Bacon PE, Panella JR, Nickoloff BJ, Miele L, Kast WM. The Notch ligand Jagged-1 is able to induce maturation of monocyte-derived human dendritic cells. J Immunol. 2002 Oct 15; 169(8):4273-8. PMID: 12370358.
      View in: PubMed
    118. Eiben GL, Velders MP, Schreiber H, Cassetti MC, Pullen JK, Smith LR, Kast WM. Establishment of an HLA-A*0201 human papillomavirus type 16 tumor model to determine the efficacy of vaccination strategies in HLA-A*0201 transgenic mice. Cancer Res. 2002 Oct 15; 62(20):5792-9. PMID: 12384540.
      View in: PubMed
    119. Fausch SC, Da Silva DM, Rudolf MP, Kast WM. Human papillomavirus virus-like particles do not activate Langerhans cells: a possible immune escape mechanism used by human papillomaviruses. J Immunol. 2002 Sep 15; 169(6):3242-9. PMID: 12218143.
      View in: PubMed
    120. Weijzen S, Rizzo P, Braid M, Vaishnav R, Jonkheer SM, Zlobin A, Osborne BA, Gottipati S, Aster JC, Hahn WC, Rudolf M, Siziopikou K, Kast WM, Miele L. Activation of Notch-1 signaling maintains the neoplastic phenotype in human Ras-transformed cells. Nat Med. 2002 Sep; 8(9):979-86. PMID: 12185362.
      View in: PubMed
    121. Salit RB, Kast WM, Velders MP. Ins and outs of clinical trials with peptide-based vaccines. Front Biosci. 2002 May 01; 7:e204-13. PMID: 11991853.
      View in: PubMed
    122. Keilholz U, Weber J, Finke JH, Gabrilovich DI, Kast WM, Disis ML, Kirkwood JM, Scheibenbogen C, Schlom J, Maino VC, Lyerly HK, Lee PP, Storkus W, Marincola F, Worobec A, Atkins MB. Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy. J Immunother. 2002 Mar-Apr; 25(2):97-138. PMID: 12074049.
      View in: PubMed
    123. Schreiber H, Wu TH, Nachman J, Kast WM. Immunodominance and tumor escape. Semin Cancer Biol. 2002 Feb; 12(1):25-31. PMID: 11926408.
      View in: PubMed
    124. Le Poole IC, Riker AI, Quevedo ME, Stennett LS, Wang E, Marincola FM, Kast WM, Robinson JK, Nickoloff BJ. Interferon-gamma reduces melanosomal antigen expression and recognition of melanoma cells by cytotoxic T cells. Am J Pathol. 2002 Feb; 160(2):521-8. PMID: 11839572.
      View in: PubMed
    125. Wakabayashi MT, Da Silva DM, Potkul RK, Kast WM. Comparison of human papillomavirus type 16 L1 chimeric virus-like particles versus L1/L2 chimeric virus-like particles in tumor prevention. Intervirology. 2002; 45(4-6):300-7. PMID: 12566713.
      View in: PubMed
    126. Eiben GL, Velders MP, Kast WM. The cell-mediated immune response to human papillomavirus-induced cervical cancer: implications for immunotherapy. Adv Cancer Res. 2002; 86:113-48. PMID: 12374277.
      View in: PubMed
    127. Mercader M, Bodner BK, Moser MT, Kwon PS, Park ES, Manecke RG, Ellis TM, Wojcik EM, Yang D, Flanigan RC, Waters WB, Kast WM, Kwon ED. T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer. Proc Natl Acad Sci U S A. 2001 Dec 04; 98(25):14565-70. PMID: 11734652.
      View in: PubMed
    128. Da Silva DM, Pastrana DV, Schiller JT, Kast WM. Effect of preexisting neutralizing antibodies on the anti-tumor immune response induced by chimeric human papillomavirus virus-like particle vaccines. Virology. 2001 Nov 25; 290(2):350-60. PMID: 11883199.
      View in: PubMed
    129. Velders MP, McElhiney S, Cassetti MC, Eiben GL, Higgins T, Kovacs GR, Elmishad AG, Kast WM, Smith LR. Eradication of established tumors by vaccination with Venezuelan equine encephalitis virus replicon particles delivering human papillomavirus 16 E7 RNA. Cancer Res. 2001 Nov 01; 61(21):7861-7. PMID: 11691804.
      View in: PubMed
    130. Yang D, Holt GE, Velders MP, Kwon ED, Kast WM. Murine six-transmembrane epithelial antigen of the prostate, prostate stem cell antigen, and prostate-specific membrane antigen: prostate-specific cell-surface antigens highly expressed in prostate cancer of transgenic adenocarcinoma mouse prostate mice. Cancer Res. 2001 Aug 01; 61(15):5857-60. PMID: 11479226.
      View in: PubMed
    131. Heller JD, Kuo J, Wu TC, Kast WM, Huang RC. Tetra-O-methyl nordihydroguaiaretic acid induces G2 arrest in mammalian cells and exhibits tumoricidal activity in vivo. Cancer Res. 2001 Jul 15; 61(14):5499-504. PMID: 11454698.
      View in: PubMed
    132. Weijzen S, Meredith SC, Velders MP, Elmishad AG, Schreiber H, Kast WM. Pharmacokinetic differences between a T cell-tolerizing and a T cell-activating peptide. J Immunol. 2001 Jun 15; 166(12):7151-7. PMID: 11390461.
      View in: PubMed
    133. Rudolf MP, Fausch SC, Da Silva DM, Kast WM. Human dendritic cells are activated by chimeric human papillomavirus type-16 virus-like particles and induce epitope-specific human T cell responses in vitro. J Immunol. 2001 May 15; 166(10):5917-24. PMID: 11342606.
      View in: PubMed
    134. Da Silva DM, Velders MP, Nieland JD, Schiller JT, Nickoloff BJ, Kast WM. Physical interaction of human papillomavirus virus-like particles with immune cells. Int Immunol. 2001 May; 13(5):633-41. PMID: 11312251.
      View in: PubMed
    135. Velders MP, Weijzen S, Eiben GL, Elmishad AG, Kloetzel PM, Higgins T, Ciccarelli RB, Evans M, Man S, Smith L, Kast WM. Defined flanking spacers and enhanced proteolysis is essential for eradication of established tumors by an epitope string DNA vaccine. J Immunol. 2001 May 01; 166(9):5366-73. PMID: 11313372.
      View in: PubMed
    136. Velders MP, ter Horst SA, Kast WM. Prospect for immunotherapy of acute lymphoblastic leukemia. Leukemia. 2001 May; 15(5):701-6. PMID: 11368429.
      View in: PubMed
    137. Gabrilovich DI, Velders MP, Sotomayor EM, Kast WM. Mechanism of immune dysfunction in cancer mediated by immature Gr-1+ myeloid cells. J Immunol. 2001 May 01; 166(9):5398-406. PMID: 11313376.
      View in: PubMed
    138. Velders MP, Macedo MF, Provenzano M, Elmishad AG, Holzhütter HG, Carbone M, Kast WM. Human T cell responses to endogenously presented HLA-A*0201 restricted peptides of Simian virus 40 large T antigen. J Cell Biochem. 2001 Apr 2-27; 82(1):155-62. PMID: 11400172.
      View in: PubMed
    139. Small LA, Da Silva DM, de Visser KE, Velders MP, Fisher SG, Potkul RK, Kast WM. A murine model for the effects of pelvic radiation and cisplatin chemotherapy on human papillomavirus vaccine efficacy. Clin Cancer Res. 2001 Mar; 7(3 Suppl):876s-881s. PMID: 11300486.
      View in: PubMed
    140. Schreiber K, Wu TH, Kast WM, Schreiber H. Tracking the common ancestry of antigenically distinct cancer variants. Clin Cancer Res. 2001 Mar; 7(3 Suppl):871s-875s. PMID: 11300485.
      View in: PubMed
    141. Rudolf MP, Man S, Melief CJ, Sette A, Kast WM. Human T-cell responses to HLA-A-restricted high binding affinity peptides of human papillomavirus type 18 proteins E6 and E7. Clin Cancer Res. 2001 Mar; 7(3 Suppl):788s-795s. PMID: 11300474.
      View in: PubMed
    142. Da Silva DM, Eiben GL, Fausch SC, Wakabayashi MT, Rudolf MP, Velders MP, Kast WM. Cervical cancer vaccines: emerging concepts and developments. J Cell Physiol. 2001 Feb; 186(2):169-82. PMID: 11169454.
      View in: PubMed
    143. Revaz V, Benyacoub J, Kast WM, Schiller JT, De Grandi P, Nardelli-Haefliger D. Mucosal vaccination with a recombinant Salmonella typhimurium expressing human papillomavirus type 16 (HPV16) L1 virus-like particles (VLPs) or HPV16 VLPs purified from insect cells inhibits the growth of HPV16-expressing tumor cells in mice. Virology. 2001 Jan 05; 279(1):354-60. PMID: 11145916.
      View in: PubMed
    144. Muderspach L, Wilczynski S, Roman L, Bade L, Felix J, Small LA, Kast WM, Fascio G, Marty V, Weber J. A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive. Clin Cancer Res. 2000 Sep; 6(9):3406-16. PMID: 10999722.
      View in: PubMed
    145. Ressing ME, van Driel WJ, Brandt RM, Kenter GG, de Jong JH, Bauknecht T, Fleuren GJ, Hoogerhout P, Offringa R, Sette A, Celis E, Grey H, Trimbos BJ, Kast WM, Melief CJ. Detection of T helper responses, but not of human papillomavirus-specific cytotoxic T lymphocyte responses, after peptide vaccination of patients with cervical carcinoma. J Immunother. 2000 Mar-Apr; 23(2):255-66. PMID: 10746552.
      View in: PubMed
    146. Jang MS, Zlobin A, Kast WM, Miele L. Notch signaling as a target in multimodality cancer therapy. Curr Opin Mol Ther. 2000 Feb; 2(1):55-65. PMID: 11249652.
      View in: PubMed
    147. Schurmans LR, den Boer AT, Diehl L, van der Voort EI, Kast WM, Melief CJ, Toes RE, Jager MJ. Successful immunotherapy of an intraocular tumor in mice. Cancer Res. 1999 Oct 15; 59(20):5250-4. PMID: 10537305.
      View in: PubMed
    148. de Visser KE, Kast WM. Effects of TGF-beta on the immune system: implications for cancer immunotherapy. Leukemia. 1999 Aug; 13(8):1188-99. PMID: 10450746.
      View in: PubMed
    149. van Driel WJ, Ressing ME, Kenter GG, Brandt RM, Krul EJ, van Rossum AB, Schuuring E, Offringa R, Bauknecht T, Tamm-Hermelink A, van Dam PA, Fleuren GJ, Kast WM, Melief CJ, Trimbos JB. Vaccination with HPV16 peptides of patients with advanced cervical carcinoma: clinical evaluation of a phase I-II trial. Eur J Cancer. 1999 Jun; 35(6):946-52. PMID: 10533477.
      View in: PubMed
    150. Nieland JD, Da Silva DM, Velders MP, de Visser KE, Schiller JT, Müller M, Kast WM. Chimeric papillomavirus virus-like particles induce a murine self-antigen-specific protective and therapeutic antitumor immune response. J Cell Biochem. 1999 May 01; 73(2):145-52. PMID: 10227378.
      View in: PubMed
    151. Ressing ME, de Jong JH, Brandt RM, Drijfhout JW, Benckhuijsen WE, Schreuder GM, Offringa R, Kast WM, Melief CJ. Differential binding of viral peptides to HLA-A2 alleles. Implications for human papillomavirus type 16 E7 peptide-based vaccination against cervical carcinoma. Eur J Immunol. 1999 04; 29(4):1292-303. PMID: 10229097.
      View in: PubMed
    152. Weijzen S, Velders MP, Kast WM. Modulation of the immune response and tumor growth by activated Ras. Leukemia. 1999 Apr; 13(4):502-13. PMID: 10214854.
      View in: PubMed
    153. Rudolf MP, Nieland JD, DaSilva DM, Velders MP, Müller M, Greenstone HL, Schiller JT, Kast WM. Induction of HPV16 capsid protein-specific human T cell responses by virus-like particles. Biol Chem. 1999 Mar; 380(3):335-40. PMID: 10223336.
      View in: PubMed
    154. Da Silva DM, Velders MP, Rudolf MP, Schiller JT, Kast WM. Papillomavirus virus-like particles as anticancer vaccines. Curr Opin Mol Ther. 1999 Feb; 1(1):82-8. PMID: 11249689.
      View in: PubMed
    155. Street M, Herd K, Londono P, Doan T, Dougan G, Kast WM, Tindle RW. Differences in the effectiveness of delivery of B- and CTL-epitopes incorporated into the hepatitis B core antigen (HBcAg) c/e1-region. Arch Virol. 1999; 144(7):1323-43. PMID: 10481740.
      View in: PubMed
    156. Velders MP, Schreiber H, Kast WM. Active immunization against cancer cells: impediments and advances. Semin Oncol. 1998 Dec; 25(6):697-706. PMID: 9865683.
      View in: PubMed
    157. Vierboom MP, Feltkamp MC, Neisig A, Drijfhout JW, ter Schegget J, Neefjes JJ, Melief CJ, Kast WM. Peptide vaccination with an anchor-replaced CTL epitope protects against human papillomavirus type 16-induced tumors expressing the wild-type epitope. J Immunother. 1998 Nov; 21(6):399-408. PMID: 9807734.
      View in: PubMed
    158. De Bruijn ML, Greenstone HL, Vermeulen H, Melief CJ, Lowy DR, Schiller JT, Kast WM. L1-specific protection from tumor challenge elicited by HPV16 virus-like particles. Virology. 1998 Oct 25; 250(2):371-6. PMID: 9792847.
      View in: PubMed
    159. Schoenberger SP, Jonges LE, Mooijaart RJ, Hartgers F, Toes RE, Kast WM, Melief CJ, Offringa R. Efficient direct priming of tumor-specific cytotoxic T lymphocyte in vivo by an engineered APC. Cancer Res. 1998 Jul 15; 58(14):3094-100. PMID: 9679976.
      View in: PubMed
    160. Nieland JD, Loviscek K, Kono K, Albain KS, McCall AR, Potkul RK, Fisher SG, Velders MP, Petersson M, Kiessling R, Kast WM. PBLs of early breast carcinoma patients with a high nuclear grade tumor unlike PBLs of cervical carcinoma patients do not show a decreased TCR zeta expression but are functionally impaired. J Immunother. 1998 Jul; 21(4):317-22. PMID: 9672853.
      View in: PubMed
    161. Toes RE, van der Voort EI, Schoenberger SP, Drijfhout JW, van Bloois L, Storm G, Kast WM, Offringa R, Melief CJ. Enhancement of tumor outgrowth through CTL tolerization after peptide vaccination is avoided by peptide presentation on dendritic cells. J Immunol. 1998 May 01; 160(9):4449-56. PMID: 9574550.
      View in: PubMed
    162. Rizzo P, Di Resta I, Powers A, Matker CM, Zhang A, Mutti L, Kast WM, Pass H, Carbone M. The detection of simian virus 40 in human tumors by polymerase chain reaction. Monaldi Arch Chest Dis. 1998 Apr; 53(2):202-10. PMID: 9689810.
      View in: PubMed
    163. Matker CM, Rizzo P, Pass HI, Di Resta I, Powers A, Mutti L, Kast WM, Carbone M. The biological activities of simian virus 40 large-T antigen and its possible oncogenic effects in humans. Monaldi Arch Chest Dis. 1998 Apr; 53(2):193-7. PMID: 9689808.
      View in: PubMed
    164. Macedo MF, Velders MP, Nieland JD, Rudolf MP, Weijzen S, Da Silva DM, Franke A, Holt G, Loviscek K, Carbone M, Kast WM. Cellular immunity and immunotherapy against deoxyribonucleic acid virus-induced tumors. Monaldi Arch Chest Dis. 1998 Apr; 53(2):211-8. PMID: 9689811.
      View in: PubMed
    165. Greenstone HL, Nieland JD, de Visser KE, De Bruijn ML, Kirnbauer R, Roden RB, Lowy DR, Kast WM, Schiller JT. Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model. Proc Natl Acad Sci U S A. 1998 Feb 17; 95(4):1800-5. PMID: 9465097.
      View in: PubMed
    166. Velders MP, Nieland JD, Rudolf MP, Loviscek K, Weijzen S, de Visser KE, Macedo MF, Carbone M, Kast WM. Identification of peptides for immunotherapy of cancer. It is worth the effort. Crit Rev Immunol. 1998; 18(1-2):7-27. PMID: 9419444.
      View in: PubMed
    167. Rizzo P, Di Resta I, Stach R, Mutti L, Picci P, Kast WM, Pass HI, Carbone M. Evidence for and implications of SV40-like sequences in human mesotheliomas and osteosarcomas. Dev Biol Stand. 1998; 94:33-40. PMID: 9776223.
      View in: PubMed
    168. Klein SC, van der Burg SH, Boer LH, Melief CJ, Kast WM, de Gast GC, Bast EJ. Targeting of cytotoxic T cells against leukemic B cells by bispecific antibody (aCD3 x aCD19) does not distract the T cell from its primary target. J Immunol. 1997 Dec 01; 159(11):5545-9. PMID: 9548495.
      View in: PubMed
    169. van der Burg SH, Klein MR, Pontesilli O, Holwerda AM, Drijfhout JW, Kast WM, Miedema F, Melief CJ. HIV-1 reverse transcriptase-specific CTL against conserved epitopes do not protect against progression to AIDS. J Immunol. 1997 Oct 01; 159(7):3648-54. PMID: 9317165.
      View in: PubMed
    170. Toes RE, Schoenberger SP, van der Voort EI, Kast WM, Hoeben RC, Melief CJ, Offringa R. Activation or frustration of anti-tumor responses by T-cell-based immune modulation. Semin Immunol. 1997 Oct; 9(5):323-7. PMID: 9327527.
      View in: PubMed
    171. Visseren MJ, van der Burg SH, van der Voort EI, Brandt RM, Schrier PI, van der Bruggen P, Boon T, Melief CJ, Kast WM. Identification of HLA-A*0201-restricted CTL epitopes encoded by the tumor-specific MAGE-2 gene product. Int J Cancer. 1997 Sep 26; 73(1):125-30. PMID: 9334819.
      View in: PubMed
    172. Vierboom MP, Nijman HW, Offringa R, van der Voort EI, van Hall T, van den Broek L, Fleuren GJ, Kenemans P, Kast WM, Melief CJ. Tumor eradication by wild-type p53-specific cytotoxic T lymphocytes. J Exp Med. 1997 Aug 29; 186(5):695-704. PMID: 9271585.
      View in: PubMed
    173. Vennegoor CJ, Nijman HW, Drijfhout JW, Vernie L, Verstraeten RA, von Mensdorff-Pouilly S, Hilgers J, Verheijen RH, Kast WM, Melief CJ, Kenemans P. Autoantibodies to p53 in ovarian cancer patients and healthy women: a comparison between whole p53 protein and 18-mer peptides for screening purposes. Cancer Lett. 1997 Jun 03; 116(1):93-101. PMID: 9177463.
      View in: PubMed
    174. van Driel WJ, Ressing ME, Brandt RM, Toes RE, Fleuren GJ, Trimbos JB, Kast WM, Melief CJ. The current status of therapeutic HPV vaccine. Ann Med. 1996 Dec; 28(6):471-7. PMID: 9017105.
      View in: PubMed
    175. Ossevoort MA, De Bruijn ML, Van Veen KJ, Kast WM, Melief CJ. Peptide specificity of alloreactive CD4 positive T lymphocytes directed against a major histocompatibility complex class I disparity. Transplantation. 1996 Nov 27; 62(10):1485-91. PMID: 8958276.
      View in: PubMed
    176. Kono K, Ressing ME, Brandt RM, Melief CJ, Potkul RK, Andersson B, Petersson M, Kast WM, Kiessling R. Decreased expression of signal-transducing zeta chain in peripheral T cells and natural killer cells in patients with cervical cancer. Clin Cancer Res. 1996 Nov; 2(11):1825-8. PMID: 9816136.
      View in: PubMed
    177. Ressing ME, Offringa R, Toes RE, Ossendorp F, de Jong JH, Brandt RM, Kast WM, Melief CJ. Immunotherapy of cancer by peptide-based vaccines for the induction of tumor-specific T cell immunity. Immunotechnology. 1996 Nov; 2(4):241-51. PMID: 9373306.
      View in: PubMed
    178. Melief CJ, Offringa R, Toes RE, Kast WM. Peptide-based cancer vaccines. Curr Opin Immunol. 1996 Oct; 8(5):651-7. PMID: 8902390.
      View in: PubMed
    179. Toes RE, Blom RJ, van der Voort E, Offringa R, Melief CJ, Kast WM. Protective antitumor immunity induced by immunization with completely allogeneic tumor cells. Cancer Res. 1996 Aug 15; 56(16):3782-7. PMID: 8706024.
      View in: PubMed
    180. Toes RE, Offringa R, Blom RJ, Melief CJ, Kast WM. Peptide vaccination can lead to enhanced tumor growth through specific T-cell tolerance induction. Proc Natl Acad Sci U S A. 1996 Jul 23; 93(15):7855-60. PMID: 8755566.
      View in: PubMed
    181. Toes RE, Kast WM, Blom RJ, Bakker SC, Offringa R, Melief CJ. Efficient tumor eradication by adoptively transferred cytotoxic T-cell clones in allogeneic hosts. Int J Cancer. 1996 May 29; 66(5):686-91. PMID: 8647633.
      View in: PubMed
    182. Toes RE, Blom RJ, Offringa R, Kast WM, Melief CJ. Enhanced tumor outgrowth after peptide vaccination. Functional deletion of tumor-specific CTL induced by peptide vaccination can lead to the inability to reject tumors. J Immunol. 1996 May 15; 156(10):3911-8. PMID: 8621930.
      View in: PubMed
    183. van der Burg SH, Visseren MJ, Brandt RM, Kast WM, Melief CJ. Immunogenicity of peptides bound to MHC class I molecules depends on the MHC-peptide complex stability. J Immunol. 1996 May 01; 156(9):3308-14. PMID: 8617954.
      View in: PubMed
    184. Ressing ME, van Driel WJ, Celis E, Sette A, Brandt MP, Hartman M, Anholts JD, Schreuder GM, ter Harmsel WB, Fleuren GJ, Trimbos BJ, Kast WM, Melief CJ. Occasional memory cytotoxic T-cell responses of patients with human papillomavirus type 16-positive cervical lesions against a human leukocyte antigen-A *0201-restricted E7-encoded epitope. Cancer Res. 1996 Feb 01; 56(3):582-8. PMID: 8564975.
      View in: PubMed
    185. Mayordomo JI, Zorina T, Storkus WJ, Zitvogel L, Celluzzi C, Falo LD, Melief CJ, Ildstad ST, Kast WM, Deleo AB. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat Med. 1995 Dec; 1(12):1297-302. PMID: 7489412.
      View in: PubMed
    186. van der Burg SH, Ras E, Drijfhout JW, Benckhuijsen WE, Bremers AJ, Melief CJ, Kast WM. An HLA class I peptide-binding assay based on competition for binding to class I molecules on intact human B cells. Identification of conserved HIV-1 polymerase peptides binding to HLA-A*0301. Hum Immunol. 1995 Dec; 44(4):189-98. PMID: 8770631.
      View in: PubMed
    187. Feltkamp MC, Vreugdenhil GR, Vierboom MP, Ras E, van der Burg SH, ter Schegget J, Melief CJ, Kast WM. Cytotoxic T lymphocytes raised against a subdominant epitope offered as a synthetic peptide eradicate human papillomavirus type 16-induced tumors. Eur J Immunol. 1995 Sep; 25(9):2638-42. PMID: 7589138.
      View in: PubMed
    188. Bremers AJ, van der Burg SH, Kuppen PJ, Kast WM, van de Velde CJ, Melief CJ. The use of Epstein-Barr virus-transformed B lymphocyte cell lines in a peptide-reconstitution assay: identification of CEA-related HLA-A*0301-restricted potential cytotoxic T-lymphocyte epitopes. J Immunother Emphasis Tumor Immunol. 1995 Aug; 18(2):77-85. PMID: 8574469.
      View in: PubMed
    189. Ossevoort MA, Feltkamp MC, van Veen KJ, Melief CJ, Kast WM. Dendritic cells as carriers for a cytotoxic T-lymphocyte epitope-based peptide vaccine in protection against a human papillomavirus type 16-induced tumor. J Immunother Emphasis Tumor Immunol. 1995 Aug; 18(2):86-94. PMID: 8574470.
      View in: PubMed
    190. Toes RE, Feltkamp MC, Ressing ME, Vierboom MP, Blom RJ, Brandt RM, Hartman M, Offringa R, Melief CJ, Kast WM. Cellular immunity against DNA tumour viruses: possibilities for peptide-based vaccines and immune escape. Biochem Soc Trans. 1995 Aug; 23(3):692-6. PMID: 8566445.
      View in: PubMed
    191. Feltkamp MC, Vierboom MP, Toes RE, Ossendorp F, ter Schegget J, Melief CJ, Kast WM. Competition inhibition of cytotoxic T-lymphocyte (CTL) lysis, a more sensitive method to identify candidate CTL epitopes than induction of antibody-detected MHC class I stabilization. Immunol Lett. 1995 Jul-Aug; 47(1-2):1-8. PMID: 8537084.
      View in: PubMed
    192. Nijman HW, Kleijmeer MJ, Ossevoort MA, Oorschot VM, Vierboom MP, van de Keur M, Kenemans P, Kast WM, Geuze HJ, Melief CJ. Antigen capture and major histocompatibility class II compartments of freshly isolated and cultured human blood dendritic cells. J Exp Med. 1995 Jul 01; 182(1):163-74. PMID: 7790816.
      View in: PubMed
    193. Hooijberg E, Sein JJ, van den Berk PC, Hart AA, van der Valk MA, Kast WM, Melief CJ, Hekman A. Eradication of large human B cell tumors in nude mice with unconjugated CD20 monoclonal antibodies and interleukin 2. Cancer Res. 1995 Jun 15; 55(12):2627-34. PMID: 7540106.
      View in: PubMed
    194. Ressing ME, Sette A, Brandt RM, Ruppert J, Wentworth PA, Hartman M, Oseroff C, Grey HM, Melief CJ, Kast WM. Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201-binding peptides. J Immunol. 1995 Jun 01; 154(11):5934-43. PMID: 7538538.
      View in: PubMed
    195. Melief CJ, Kast WM. T-cell immunotherapy of tumors by adoptive transfer of cytotoxic T lymphocytes and by vaccination with minimal essential epitopes. Immunol Rev. 1995 Jun; 145:167-77. PMID: 7590825.
      View in: PubMed
    196. Kleijmeer MJ, Ossevoort MA, van Veen CJ, van Hellemond JJ, Neefjes JJ, Kast WM, Melief CJ, Geuze HJ. MHC class II compartments and the kinetics of antigen presentation in activated mouse spleen dendritic cells. J Immunol. 1995 Jun 01; 154(11):5715-24. PMID: 7751623.
      View in: PubMed
    197. Van Elsas A, Nijman HW, Van der Minne CE, Mourer JS, Kast WM, Melief CJ, Schrier PI. Induction and characterization of cytotoxic T-lymphocytes recognizing a mutated p21ras peptide presented by HLA-A*0201. Int J Cancer. 1995 May 04; 61(3):389-96. PMID: 7729952.
      View in: PubMed
    198. D'Amaro J, Houbiers JG, Drijfhout JW, Brandt RM, Schipper R, Bavinck JN, Melief CJ, Kast WM. A computer program for predicting possible cytotoxic T lymphocyte epitopes based on HLA class I peptide-binding motifs. Hum Immunol. 1995 May; 43(1):13-8. PMID: 7558924.
      View in: PubMed
    199. Drijfhout JW, Brandt RM, D'Amaro J, Kast WM, Melief CJ. Detailed motifs for peptide binding to HLA-A*0201 derived from large random sets of peptides using a cellular binding assay. Hum Immunol. 1995 May; 43(1):1-12. PMID: 7558923.
      View in: PubMed
    200. Visseren MJ, van Elsas A, van der Voort EI, Ressing ME, Kast WM, Schrier PI, Melief CJ. CTL specific for the tyrosinase autoantigen can be induced from healthy donor blood to lyse melanoma cells. J Immunol. 1995 Apr 15; 154(8):3991-8. PMID: 7706738.
      View in: PubMed
    201. Toes RE, Offringa R, Blom RJ, Brandt RM, van der Eb AJ, Melief CJ, Kast WM. An adenovirus type 5 early region 1B-encoded CTL epitope-mediating tumor eradication by CTL clones is down-modulated by an activated ras oncogene. J Immunol. 1995 Apr 01; 154(7):3396-405. PMID: 7534797.
      View in: PubMed
    202. Neisig A, Roelse J, Sijts AJ, Ossendorp F, Feltkamp MC, Kast WM, Melief CJ, Neefjes JJ. Major differences in transporter associated with antigen presentation (TAP)-dependent translocation of MHC class I-presentable peptides and the effect of flanking sequences. J Immunol. 1995 Feb 01; 154(3):1273-9. PMID: 7822796.
      View in: PubMed
    203. van der Burg SH, Klein MR, van de Velde CJ, Kast WM, Miedema F, Melief CJ. Induction of a primary human cytotoxic T-lymphocyte response against a novel conserved epitope in a functional sequence of HIV-1 reverse transcriptase. AIDS. 1995 Feb; 9(2):121-7. PMID: 7536421.
      View in: PubMed
    204. Grey HM, Ruppert J, Vitiello A, Sidney J, Kast WM, Kubo RT, Sette A. Class I MHC-peptide interactions: structural requirements and functional implications. Cancer Surv. 1995; 22:37-49. PMID: 7536628.
      View in: PubMed
    205. Ossevoort MA, Kleijmeer MJ, Nijman HW, Geuze HJ, Kast WM, Melief CJ. Functional and ultrastructural aspects of antigen processing by dendritic cells. Adv Exp Med Biol. 1995; 378:227-31. PMID: 8526062.
      View in: PubMed
    206. Sette A, Vitiello A, Reherman B, Fowler P, Nayersina R, Kast WM, Melief CJ, Oseroff C, Yuan L, Ruppert J, Sidney J, del Guercio MF, Southwood S, Kubo RT, Chesnut RW, Grey HM, Chisari FV. The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes. J Immunol. 1994 Dec 15; 153(12):5586-92. PMID: 7527444.
      View in: PubMed
    207. Feltkamp MC, Vierboom MP, Kast WM, Melief CJ. Efficient MHC class I-peptide binding is required but does not ensure MHC class I-restricted immunogenicity. Mol Immunol. 1994 Dec; 31(18):1391-401. PMID: 7823965.
      View in: PubMed
    208. Sijts AJ, De Bruijn ML, Ressing ME, Nieland JD, Mengedé EA, Boog CJ, Ossendorp F, Kast WM, Melief CJ. Identification of an H-2 Kb-presented Moloney murine leukemia virus cytotoxic T-lymphocyte epitope that displays enhanced recognition in H-2 Db mutant bm13 mice. J Virol. 1994 Sep; 68(9):6038-46. PMID: 7520098.
      View in: PubMed
    209. Toes RE, Offringa R, Feltkamp MC, Visseren MJ, Schoenberger SP, Melief CJ, Kast WM. Tumor rejection antigens and tumor specific cytotoxic T lymphocytes. Behring Inst Mitt. 1994 Jul; (94):72-86. PMID: 7998917.
      View in: PubMed
    210. Nijman HW, Van der Burg SH, Vierboom MP, Houbiers JG, Kast WM, Melief CJ. p53, a potential target for tumor-directed T cells. Immunol Lett. 1994 May; 40(2):171-8. PMID: 8088874.
      View in: PubMed
    211. Kast WM, Brandt RM, Sidney J, Drijfhout JW, Kubo RT, Grey HM, Melief CJ, Sette A. Role of HLA-A motifs in identification of potential CTL epitopes in human papillomavirus type 16 E6 and E7 proteins. J Immunol. 1994 Apr 15; 152(8):3904-12. PMID: 7511661.
      View in: PubMed
    212. Visseren MJ, Koot M, van der Voort EI, Gravestein LA, Schoenmakers HJ, Kast WM, Zijlstra M, Melief CJ. Production of interleukin-2 by EL4 tumor cells induces natural killer cell- and T-cell-mediated immunity. J Immunother Emphasis Tumor Immunol. 1994 Feb; 15(2):119-28. PMID: 8136944.
      View in: PubMed
    213. Melief CJ, Kast WM. Prospects for T cell immunotherapy of tumours by vaccination with immunodominant and subdominant peptides. Ciba Found Symp. 1994; 187:97-104; discussion 104-12. PMID: 7796678.
      View in: PubMed
    214. Ossevoort MA, Sijts AJ, van Veen KJ, Momburg F, Hämmerling GJ, Seelig A, Butcher GW, Howard JC, Kast WM, Melief CJ. Differential effect of transporter Tap 2 gene introduction into RMA-S cells on viral antigen processing. Eur J Immunol. 1993 Dec; 23(12):3082-8. PMID: 8258321.
      View in: PubMed
    215. Feltkamp MC, Smits HL, Vierboom MP, Minnaar RP, de Jongh BM, Drijfhout JW, ter Schegget J, Melief CJ, Kast WM. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur J Immunol. 1993 Sep; 23(9):2242-9. PMID: 7690326.
      View in: PubMed
    216. Houbiers JG, Nijman HW, van der Burg SH, Drijfhout JW, Kenemans P, van de Velde CJ, Brand A, Momburg F, Kast WM, Melief CJ. In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild-type p53. Eur J Immunol. 1993 Sep; 23(9):2072-7. PMID: 8370389.
      View in: PubMed
    217. Kast WM, Brandt RM, Drijfhout JW, Melief CJ. Human leukocyte antigen-A2.1 restricted candidate cytotoxic T lymphocyte epitopes of human papillomavirus type 16 E6 and E7 proteins identified by using the processing-defective human cell line T2. J Immunother Emphasis Tumor Immunol. 1993 Aug; 14(2):115-20. PMID: 7506573.
      View in: PubMed
    218. Nijman HW, Houbiers JG, van der Burg SH, Vierboom MP, Kenemans P, Kast WM, Melief CJ. Characterization of cytotoxic T lymphocyte epitopes of a self-protein, p53, and a non-self-protein, influenza matrix: relationship between major histocompatibility complex peptide binding affinity and immune responsiveness to peptides. J Immunother Emphasis Tumor Immunol. 1993 Aug; 14(2):121-6. PMID: 7506574.
      View in: PubMed
    219. Toes RE, den Haan JM, Feltkamp MC, Blom RJ, Melief CJ, Claassen E, Kast WM. In vivo detection of fluorescent tumor-specific cytotoxic T cell clones. J Immunol Methods. 1993 Jul 06; 163(1):23-32. PMID: 8393053.
      View in: PubMed
    220. Wykes MN, Shellam GR, McCluskey J, Kast WM, Dallas PB, Price P. Murine cytomegalovirus interacts with major histocompatibility complex class I molecules to establish cellular infection. J Virol. 1993 Jul; 67(7):4182-9. PMID: 8389923.
      View in: PubMed
    221. Nijman HW, Houbiers JG, Vierboom MP, van der Burg SH, Drijfhout JW, D'Amaro J, Kenemans P, Melief CJ, Kast WM. Identification of peptide sequences that potentially trigger HLA-A2.1-restricted cytotoxic T lymphocytes. Eur J Immunol. 1993 Jun; 23(6):1215-9. PMID: 7684681.
      View in: PubMed
    222. Kast WM, Brandt RM, Melief CJ. Strict peptide length is not required for the induction of cytotoxic T lymphocyte-mediated antiviral protection by peptide vaccination. Eur J Immunol. 1993 May; 23(5):1189-92. PMID: 8386667.
      View in: PubMed
    223. Ossevoort MA, Toes RE, De Bruijn ML, Melief CJ, Figdor CG, Kast WM. The MHC expression of dendritic cells from mouse spleen isolated by centrifugal elutriation is upregulated during short term culture. Adv Exp Med Biol. 1993; 329:185-9. PMID: 8379369.
      View in: PubMed
    224. De Bruijn ML, Nieland JD, Schumacher TN, Ploegh HL, Kast WM, Melief CJ. Mechanisms of induction of primary virus-specific cytotoxic T lymphocyte responses. Eur J Immunol. 1992 Nov; 22(11):3013-20. PMID: 1425925.
      View in: PubMed
    225. Ossevoort MA, Toes RE, De Bruijn ML, Melief CJ, Figdor CG, Kast WM. A rapid isolation procedure for dendritic cells from mouse spleen by centrifugal elutriation. J Immunol Methods. 1992 Oct 19; 155(1):101-11. PMID: 1328395.
      View in: PubMed
    226. Sijts AJ, De Bruijn ML, Nieland JD, Kast WM, Melief CJ. Cytotoxic T lymphocytes against the antigen-processing-defective RMA-S tumor cell line. Eur J Immunol. 1992 Jun; 22(6):1639-42. PMID: 1601045.
      View in: PubMed
    227. Melief CJ, Kast WM. Lessons from T cell responses to virus induced tumours for cancer eradication in general. Cancer Surv. 1992; 13:81-99. PMID: 1423326.
      View in: PubMed
    228. De Bruijn ML, Schumacher TN, Nieland JD, Ploegh HL, Kast WM, Melief CJ. Peptide loading of empty major histocompatibility complex molecules on RMA-S cells allows the induction of primary cytotoxic T lymphocyte responses. Eur J Immunol. 1991 Dec; 21(12):2963-70. PMID: 1660811.
      View in: PubMed
    229. van Twuyver E, Mooijaart RJ, ten Berge IJ, van der Horst AR, Wilmink JM, Kast WM, Melief CJ, de Waal LP. Pretransplantation blood transfusion revisited. N Engl J Med. 1991 Oct 24; 325(17):1210-3. PMID: 1922208.
      View in: PubMed
    230. Kast WM, Melief CJ. In vivo efficacy of virus-derived peptides and virus-specific cytotoxic T lymphocytes. Immunol Lett. 1991 Oct; 30(2):229-32. PMID: 1757108.
      View in: PubMed
    231. Melief CJ, Kast WM. Cytotoxic T lymphocyte therapy of cancer and tumor escape mechanisms. Semin Cancer Biol. 1991 Oct; 2(5):347-54. PMID: 1773050.
      View in: PubMed
    232. Melief CJ, Kast WM. T-cell immunotherapy of cancer. Res Immunol. 1991 Jun-Aug; 142(5-6):425-9. PMID: 1754715.
      View in: PubMed
    233. Schumacher TN, De Bruijn ML, Vernie LN, Kast WM, Melief CJ, Neefjes JJ, Ploegh HL. Peptide selection by MHC class I molecules. Nature. 1991 Apr 25; 350(6320):703-6. PMID: 1708852.
      View in: PubMed
    234. Kast WM, Roux L, Curren J, Blom HJ, Voordouw AC, Meloen RH, Kolakofsky D, Melief CJ. Protection against lethal Sendai virus infection by in vivo priming of virus-specific cytotoxic T lymphocytes with a free synthetic peptide. Proc Natl Acad Sci U S A. 1991 Mar 15; 88(6):2283-7. PMID: 1848698.
      View in: PubMed
    235. de Waal LP, van Twuyver E, Mooijaart RJ, Lardy NM, Kast WM, Melief CJ. Mechanisms of transplantation tolerance: do anti-idiotypic antibodies play a role? Transplant Proc. 1991 Feb; 23(1 Pt 1):155-6. PMID: 1824971.
      View in: PubMed
    236. Kast WM, Melief CJ. Fine peptide specificity of cytotoxic T lymphocytes directed against adenovirus-induced tumours and peptide-MHC binding. Int J Cancer Suppl. 1991; 6:90-4. PMID: 2066186.
      View in: PubMed
    237. van Twuyver E, Mooijaart RJ, Kast WM, Melief CJ, de Waal LP. Different requirements for the regulation of transplantation tolerance induction for allogeneic versus xenogeneic major histocompatibility complex antigens. Hum Immunol. 1990 Nov; 29(3):220-8. PMID: 2283336.
      View in: PubMed
    238. Kast WM, Bluestone JA, Heemskerk MH, Spaargaren J, Voordouw AC, Ellenhorn JD, Melief CJ. Treatment with monoclonal anti-CD3 antibody protects against lethal Sendai virus infection by induction of natural killer cells. J Immunol. 1990 Oct 01; 145(7):2254-9. PMID: 2168920.
      View in: PubMed
    239. Schumacher TN, Heemels MT, Neefjes JJ, Kast WM, Melief CJ, Ploegh HL. Direct binding of peptide to empty MHC class I molecules on intact cells and in vitro. Cell. 1990 Aug 10; 62(3):563-7. PMID: 2199065.
      View in: PubMed
    240. van den Heuvel SJ, van Laar T, Kast WM, Melief CJ, Zantema A, van der Eb AJ. Association between the cellular p53 and the adenovirus 5 E1B-55kd proteins reduces the oncogenicity of Ad-transformed cells. EMBO J. 1990 Aug; 9(8):2621-9. PMID: 2142453.
      View in: PubMed
    241. Melief CJ, Kast WM. Efficacy of cytotoxic T lymphocytes against virus-induced tumors. Cancer Cells. 1990 Apr; 2(4):116-20. PMID: 2143919.
      View in: PubMed
    242. Kast WM, Offringa R, Peters PJ, Voordouw AC, Meloen RH, van der Eb AJ, Melief CJ. Eradication of adenovirus E1-induced tumors by E1A-specific cytotoxic T lymphocytes. Cell. 1989 Nov 17; 59(4):603-14. PMID: 2555063.
      View in: PubMed
    243. van Twuyver E, Kast WM, Mooijaart RJ, Wilmink JM, Melief CJ, de Waal LP. Allograft tolerance induction in adult mice associated with functional deletion of specific CTL precursors. Transplantation. 1989 Nov; 48(5):844-7. PMID: 2815256.
      View in: PubMed
    244. Stam NJ, Kast WM, Voordouw AC, Pastoors LB, van der Hoeven FA, Melief CJ, Ploegh HL. Lack of correlation between levels of MHC class I antigen and susceptibility to lysis of small cellular lung carcinoma (SCLC) by natural killer cells. J Immunol. 1989 Jun 01; 142(11):4113-7. PMID: 2541206.
      View in: PubMed
    245. van Twuyver E, Kast WM, Mooijaart RJ, Melief CJ, de Waal LP. Transfusion-induced skin allograft enhancement across an H-2 class-I mismatch is caused by a clonal deletion of donor-specific cytotoxic T-lymphocyte precursors within the allograft. Transplant Proc. 1989 Feb; 21(1 Pt 1):1169-70. PMID: 2650087.
      View in: PubMed
    246. Melief CJ, Vasmel WL, Offringa R, Sijts EJ, Matthews EA, Peters PJ, Meloen RH, van der Eb AJ, Kast WM. Immunosurveillance of virus-induced tumors. Cold Spring Harb Symp Quant Biol. 1989; 54 Pt 1:597-603. PMID: 2700948.
      View in: PubMed
    247. Kast WM, Van Twuyver E, Mooijaart RJ, Verveld M, Kamphuis AG, Melief CJ, De Waal LP. Mechanism of skin allograft enhancement across an H-2 class I mutant difference. Evidence for involvement of veto cells. Eur J Immunol. 1988 Dec; 18(12):2105-8. PMID: 2975604.
      View in: PubMed
    248. Kast WM, Boog CJ, Roep BO, Voordouw AC, Melief CJ. Failure or success in the restoration of virus-specific cytotoxic T lymphocyte response defects by dendritic cells. J Immunol. 1988 May 01; 140(9):3186-93. PMID: 2834454.
      View in: PubMed
    249. Melief CJ, Boog CJ, Vasmel WL, Boes J, Voordouw AC, Kast WM. Dendritic cells and antigen presentation in the regulation of cytotoxic T lymphocyte responses against viruses and transplantation antigens. Ann N Y Acad Sci. 1988; 532:280-91. PMID: 2845847.
      View in: PubMed
    250. Kast WM, Voordouw AC, Leupers T, Visser JW, Melief CJ. Thymic immune response gene function in radiation chimeras reconstituted with purified hemopoietic stem cells. Eur J Immunol. 1987 Apr; 17(4):471-5. PMID: 3106065.
      View in: PubMed
    251. Kast WM, Bronkhorst AM, de Waal LP, Melief CJ. Cooperation between cytotoxic and helper T lymphocytes in protection against lethal Sendai virus infection. Protection by T cells is MHC-restricted and MHC-regulated; a model for MHC-disease associations. J Exp Med. 1986 Sep 01; 164(3):723-38. PMID: 3018121.
      View in: PubMed
    252. Cochet M, Kast WM, Kummer AM, Transy C, Melief CJ, Kourilsky P. Alternative splicing in the mouse H-2Kd gene is not necessary for the classical Kd antigen function. Immunogenetics. 1986; 24(4):267-74. PMID: 3491042.
      View in: PubMed
    253. Boog CJ, Kast WM, Timmers HT, Boes J, de Waal LP, Melief CJ. Abolition of specific immune response defect by immunization with dendritic cells. Nature. 1985 Nov 7-13; 318(6041):59-62. PMID: 2932649.
      View in: PubMed
    254. Kast WM, de Waal LP, Melief CJ. Thymus dictates major histocompatibility complex (MHC) specificity and immune response gene phenotype of class II MHC-restricted T cells but not of class I MHC-restricted T cells. J Exp Med. 1984 Dec 01; 160(6):1752-66. PMID: 6096476.
      View in: PubMed
    255. Melief CJ, Stukart MJ, de Waal LP, Kast WM, Melvold RW. Specificity and regulation of cytotoxic T-lymphocyte responses analyzed with H-2 mutants. Transplant Proc. 1983 Dec; 15(4):2086-9. PMID: 6324427.
      View in: PubMed
    256. de Waal LP, Kast WM, Melvold RW, Melief CJ. Regulation of the cytotoxic T lymphocyte response against Sendai virus analyzed with H-2 mutants. J Immunol. 1983 Mar; 130(3):1090-6. PMID: 6185570.
      View in: PubMed